Email Updates

Search form

You are here

PrEP

Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

The Australian government announced on May 8 that it would invest AU$180 million (or $134 million in US money) in PrEP funding. The government also added PrEP to Australia's Pharmaceutical Benefits Scheme (PBS), the list of drugs approved for government-funded subsidies through the national healthcare plan.

May 11, 2018
Seattle Gay News

Truvada was approved as an HIV prevention method in 2012 but only for individuals age 18 and older. The new approval expands this indication to include adults and adolescents at risk for HIV.

May 15, 2018
POZ

New findings show that nearly a fifth of adults whose risk for HIV infection made them eligible for free PrEP - medicine to protect them from the virus- started taking the drug within 30 days, according to a study examining the impacts of health interventions across communities in two East African countries. The study’s authors conclude that this provides further evidence, with caveats, that widespread roll out of PrEP to individuals at high risks for infection across resource-limited communities is feasible.

May 9, 2018
Infectious Diseases Society of America: Science Speaks

Australia's federal government has announced it will list an effective HIV prevention drug on the Pharmaceutical Benefits Scheme (PBS), starting next month. Health Minister Greg Hunt today confirmed that pre-exposure prophylaxis, known as PrEP, would be government subsidized from April 1.

March 21, 2018
Australia's Nine News
Subscribe to RSS - PrEP